Graf Acquisition Partners IV LLC - Sep 29, 2023 Form 4 Insider Report for NKGen Biotech, Inc. (GFOR)

Role
10%+ Owner
Signature
/s/ James A. Graf, managing member of Graf Acquisition Partners IV LLC
Stock symbol
GFOR
Transactions as of
Sep 29, 2023
Transactions value $
$7,867,010
Form type
4
Date filed
10/4/2023, 06:10 AM
Previous filing
Jul 14, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GFOR Common Stock Other $0 -1.77M -42.13% $0.00 2.44M Sep 29, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GFOR Private Placement Warrants Award $7.08M +4.72M $1.50* 4.72M Sep 29, 2023 Common Stock 4.72M $11.50 Direct F2, F3
transaction GFOR Working Capital Warrants Award $785K +523K +11.08% $1.50* 5.24M Sep 29, 2023 Common Stock 523K $11.50 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On September 29, 2023, Graf Acquisition Partners IV LLC (the "Sponsor") forfeited 1,773,631 shares of common stock of the NKGen Biotech, Inc. (f/k/a Graf Acquisition Corp. IV, the "Issuer") held by it back to the Issuer for no consideration in connection with the closing of the Issuer's business combination transaction (the "Closing").
F2 The Sponsor is the record holder of the securities reported herein. James A. Graf is the managing member of the Sponsor. Mr. Graf has voting and investment discretion with respect to the securities held of record by the Sponsor.
F3 The Private Placement Warrants are reported as acquired for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), concurrent with the Closing, because, pursuant to their terms, their exercise was not within the control of the Reporting Persons until the Closing. The Private Placement Warrants were initially acquired in a private placement from the Issuer concurrent with Issuer's initial public offering.
F4 The Working Capital Warrants were issued to the Sponsor concurrently with the Closing pursuant to a working capital note between the Sponsor and the Issuer.